Abstract:Abstract Background Butyrate is the most beneficial among short-chain fatty acids (SCFA’s) that plays a key role in intestinal homeostasis by modifying: gut microbiome, gut barrier integrity, and reducing inflammation. There are some evidence of its usefulness in the treatment of Ulcerative Colitis (UC), however the data are not clear. The aim of our study was to assess the efficacy and safety of oral microencapsulated sodium butyrate (MSB) as add-on treatment in induction of remission in active UC. Methods 100 patients with mild to moderate UC were enrolled in the study and randomized to MSB group treated with 2x300 mg/d of butyrate or placebo group (C); 96 of those patients completed all study protocol. Total Mayo Score (TMS), endoscopic images and fecal calprotectin were investigated to estimate the effect of MSB administration in induction remission, as well as relation between fecal butyrate concentrations (C4) and effectiveness of treatment. Results Clinical and endoscopic improvement (p < 0.001 and p = 0.042) and clinical remission (p < 0.001) was observed in MSB group. Accordingly, an improvement in the endoscopic image(defined as Mayo Score (MS) difference ≥ 1) at 8 weeks of follow up was achieved in 26patients (55.3%) in the study group and 16 (32.7%) in placebo group (p=0.042). Clinical improvement (defined as TMS difference ≥ 3) was observed in 39 (83%) study group patients and 15 (30.6%) in placebo group (p < 0.001). Clinical remission (TMS at visit 2 ≤ 2) was obtained in 30 (63.84%) MSB group patients and 11 (22.4%) in control group (p < 0.001). Significant improvement was also expressed as reduction of calprotectin level. In MSB group significant increase of C4 was observed in the group with clinical improvement, clinical remission and endoscopic improvement, and it was significantly higher than among non-responders. (MD =1.35 CI 95 [0.51;3.56], p < 0.001), clinical remission (MD = 1.69 CI 95 [0.44;3.45], p = 0.001) and endoscopic improvement (MD = 1.99 CI 95 [0.84;2.82], (p < 0.001)). In C group the level of C4 was significantly lower, regardless of clinical response. No side effects was observed during treatment. Conclusion MSB supplementation increases the fecal butyrate concentration and results in clinical remission and endoscopic improvement in mild to moderate UC. Our study clearly showed that MSB appears to be a beneficial and safe add-on treatment of those patients.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the effectiveness and safety of oral microencapsulated sodium butyrate (MSB) as an adjunctive treatment in inducing remission in patients with mild - to - moderate ulcerative colitis (UC). ### Background Butyrate is the most beneficial among short - chain fatty acids (SCFAs). It plays a crucial role in maintaining intestinal homeostasis by regulating the gut microbiota, enhancing intestinal barrier integrity and reducing inflammation. Although there is some evidence suggesting that butyrate may be useful in the treatment of UC, these data are still unclear. ### Research Objectives This study aims to evaluate the effectiveness and safety of oral microencapsulated sodium butyrate (MSB) as an adjunctive treatment in inducing clinical remission in patients with mild - to - moderate UC. ### Methods The study included 100 patients with mild - to - moderate UC and randomly assigned them to the MSB group (300 mg of butyrate twice a day) or the placebo group (C). A total of 96 patients completed the entire study protocol. The study used the Total Mayo Score (TMS), endoscopic images and fecal calprotectin levels to evaluate the effect of MSB in inducing remission, and also evaluated the relationship between fecal butyrate concentration (C4) and treatment effect. ### Results The results showed that: - Clinical and endoscopic improvements (p < 0.001 and p = 0.042) and clinical remission (p < 0.001) were significantly observed in the MSB group. - At the 8 - week follow - up, 26 patients (55.3%) in the MSB group and 16 patients (32.7%) in the placebo group achieved improvement in endoscopic images (defined as a Mayo score difference ≥ 1), with a significant difference (p = 0.042). - Clinical improvement (defined as a TMS difference ≥ 3) was observed in 39 patients (83%) in the MSB group and 15 patients (30.6%) in the placebo group (p < 0.001). - Clinical remission (TMS ≤ 2 at the second visit) was achieved in 30 patients (63.84%) in the MSB group and 11 patients (22.4%) in the placebo group (p < 0.001). - In the MSB group, the fecal butyrate concentration (C4) in patients with clinical improvement, clinical remission and endoscopic improvement increased significantly and was significantly higher than that in non - responders (MD = 1.35, CI 95 [0.51; 3.56], p < 0.001; MD = 1.69, CI 95 [0.44; 3.45], p = 0.001; MD = 1.99, CI 95 [0.84; 2.82], p < 0.001). - In the placebo group, the C4 level was significantly lower regardless of whether there was a clinical response. No side effects were observed during the treatment. ### Conclusion Supplementation with MSB can increase the butyrate concentration in feces and induce clinical remission and endoscopic improvement in patients with mild - to - moderate UC. The study shows that MSB, as an adjunctive treatment, is beneficial and safe for these patients.

P876 Efficacy and safety of microencapsulated butyrate add-on therapy in induction of remission in patients with mild-to-moderate Ulcerative Colitis - results from multi-center, double-blind, randomized, placebo-controlled clinical study

P859 Sodium Butyrate supplementation significantly improved clinical outcomes and quality of life in patients with Crohn’s Disease – results from a randomized placebo-controlled study

P658 Safety and efficacy of MH002, an optimized live biotherapeutic product, for the treatment of mild to moderate ulcerative colitis: a first-in-disease, double-blind, randomized clinical trial

Effect of butyrate enemas on inflammation and antioxidant status in the colonic mucosa of patients with ulcerative colitis in remission

Oral administration of sodium butyrate attenuates inflammation and mucosal lesion in experimental acute ulcerative colitis

Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double‐blinded, placebo‐controlled multicenter trial

P1208 MH002, an optimized live biotherapeutic product, for the treatment of inflammatory bowel diseases, has mode-of-actions linked to restoration of intestinal dysbiosis, mucosal integrity, and immune homeostasis

P036 Microbiota Metabolite Butyrate Attenuates Intestinal Inflammation Through Autophagy Activation

A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF PSYLLIUM FIBER AND FECAL MICROBIOTA TRANSPLANTATION FOR MILD TO MODERATE ULCERATIVE COLITIS

Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis

P600 Efficacy of different modalities of faecal microbiota transplantation to induce clinical remission in patients with ulcerative colitis: a systematic review and network meta-analysis

Comparative efficacy and tolerability of probiotic, prebiotic, and synbiotic formulations for adult patients with mild-moderate ulcerative colitis in an adjunctive therapy: a network meta-analysis

Efficacy and safety of berberine plus 5-ASA for ulcerative colitis: A systematic review and meta-analysis

Efficacy and Safety of Advanced Therapies in Moderately-to-Severely Active Ulcerative Colitis: a Systematic Review and Network Meta-analysis

Additive efficacy and safety of probiotics in the treatment of ulcerative colitis: a systematic review and meta-analysis

P879 Comparative Efficacy of Biologics and Small Molecule Therapies for the Induction and Maintenance of Endoscopic and Histological Remission in Ulcerative Colitis: A Systematic Review and Network Meta-analysis

A Pragmatic Randomised Controlled Study to Assess the Effectiveness of Two Patient Management Strategies in Mild to Moderate Ulcerative Colitis—The OPTIMISE Study

Effect of butyrate enemas on gene expression profiles and endoscopic/histopathological scores of diverted colorectal mucosa: A randomized trial

P1209 Baseline gut microbiota composition and function reflect response to 5-ASA treatment in Ulcerative Colitis

P533 Photo Biomodulation treatment in patients with Ulcerative Colitis

P793 Efficacy and safety of probiotics in inflammatory bowel disease: an umbrella review and updated meta-analysis of randomized controlled trials